Latest Osteoarthritis News

Paradigm Biopharmaceuticals has achieved 50% patient enrolment in its pivotal Phase 3 trial for injectable pentosan polysulfate sodium, advancing steadily towards an interim analysis expected in August 2026.

Cynata Therapeutics has completed the 100-day primary evaluation period for its Phase 2 trial of CYP-001 in acute graft versus host disease, with results expected in June 2026. This milestone marks a critical step for the biotech’s lead cell therapy candidate in a condition with few effective treatments.

Paradigm Biopharmaceuticals reports a sharp rise in half-year losses as it intensifies investment in its pivotal Phase 3 trial for knee osteoarthritis, setting sights on a critical interim analysis in mid-2026. The company also expands its osteoarthritis pipeline and maintains strong funding amid a strengthening biotech sector.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.

Paradigm Biopharmaceuticals has published a pivotal study in PLOS ONE showing sustained pain relief and joint repair in dogs treated with pentosan polysulfate sodium, reinforcing its potential for human osteoarthritis therapy.

Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Cynata Therapeutics has completed enrolment in major clinical trials for osteoarthritis and acute graft versus host disease, with pivotal results expected in the second quarter of 2026. The company also strengthened its patent portfolio and secured additional funding to extend its operational runway.

Paradigm Biopharmaceuticals has secured independent validation of its Phase 2 iPPS biomarker study, published in a leading rheumatology journal, reinforcing the scientific basis for its Phase 3 osteoarthritis trial.

Cynata Therapeutics has successfully raised $1.2 million through an At-The-Market equity raise, issuing shares at a discount to support its ongoing clinical programs. This capital injection aims to bolster working capital as the company advances its proprietary stem cell therapies.

Cynata Therapeutics has completed the final patient visit in its Phase 3 trial for CYP-004, targeting knee osteoarthritis, with results expected in mid-2026. This milestone advances hopes for a disease-modifying therapy in a market desperate for new options.